← Leaderboards
Jack T Stapleton
University Of Iowa
$10,711,351
Attributed
$11,511,882
Total exposure
29
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $961.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,511,882 · 27
VA$0 · 2
By mechanism
R01$6,002,424 · 2
T32$4,354,971 · 1
R56$538,304 · 1
R21$325,345 · 1
M01$290,838 · 21
P01$0 · 1
Top collaborators
- Lee-Ann H. Allen5 shared
- Jon C.D. Houtman1 shared
Most similar at University Of Iowa
Same institution · by research overlap
- Robert Bruce Wallace$4,552,812
- Jon C.d. Houtman$3,680,952
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsHuman Therapy EvaluationAids TherapyMediatingIn VitroAntiaids AgentInfectionImmuneCellsT-LymphocyteVirusCommunicable DiseasesIn VivoNovel StrategiesCombination ChemotherapyBaseImmune ResponseLymphocyteProteinsViralDrug Screening /EvaluationAntiviral Therapy
Grant awards (100)
SARS CoV-2 Immune Evasion Mechanisms$0
I01 · FY2025 · VA · contact PI
Research Training in Infectious Diseases$295,686
T32 · FY2024 · AI · contact PI
SARS CoV-2 Immune Evasion Mechanisms$0
I01 · FY2024 · VA · contact PI
Research Training in Infectious Diseases$260,661
T32 · FY2023 · AI · contact PI
SARS CoV-2 Immune Evasion Mechanisms$0
I01 · FY2023 · VA · contact PI
Research Training in Infectious Diseases$250,947
T32 · FY2022 · AI · contact PI
SARS CoV-2 Immune Evasion Mechanisms$0
I01 · FY2022 · VA · contact PI
Research Training in Infectious Diseases$241,093
T32 · FY2021 · AI · contact PI
Research Training in Infectious Diseases$239,296
T32 · FY2020 · AI · contact PI
Novel viral immune interference mechanisms: HCV as a model system$0
I01 · FY2020 · VA · contact PI
Research Training In Infectious Diseases$236,934
T32 · FY2019 · AI · contact PI
Novel viral immune interference mechanisms: HCV as a model system$0
I01 · FY2019 · VA · contact PI
Research Training In Infectious Diseases$220,450
T32 · FY2018 · AI · contact PI
Novel viral immune interference mechanisms: HCV as a model system$0
I01 · FY2018 · VA · contact PI
The role of HCV RNA-targeted phosphatase PTPRE in T cell activation$538,304
R56 · FY2017 · AI · contact PI
Research Training In Infectious Diseases$218,760
T32 · FY2017 · AI · contact PI
Novel viral immune interference mechanisms: HCV as a model system$0
I01 · FY2017 · VA · contact PI
Research Training In Infectious Diseases$171,647
T32 · FY2016 · AI · contact PI
GB Virus C and Non-Hodgkins Lymphoma Risk and Prognosis$0
I01 · FY2016 · VA · contact PI
The effects of hepatitis C virus (HCV) E2 protein on host immunomodulation$0
I01 · FY2016 · VA · contact PI
Research Training In Infectious Diseases$214,968
T32 · FY2015 · AI · contact PI
GB Virus C and Non-Hodgkins Lymphoma Risk and Prognosis$0
I01 · FY2015 · VA · contact PI
The effects of hepatitis C virus (HCV) E2 protein on host immunomodulation$0
I01 · FY2015 · VA · contact PI
Research Training in Infectious Diseases$175,731
T32 · FY2014 · AI · contact PI
The effects of hepatitis C virus (HCV) E2 protein on host immunomodulation$0
I01 · FY2014 · VA · contact PI
GB Virus C and Non-Hodgkins Lymphoma Risk and Prognosis$0
I01 · FY2014 · VA · contact PI
Research Training in Infectious Diseases$207,416
T32 · FY2013 · AI · contact PI
The effects of hepatitis C virus (HCV) E2 protein on host immunomodulation$0
I01 · FY2013 · VA · contact PI
GB Virus C and Non-Hodgkins Lymphoma Risk and Prognosis$0
I01 · FY2013 · VA · contact PI
GBV-C effects on CD4 activation and expansion$529,116
R01 · FY2012 · AI · contact PI
Research Training in Infectious Diseases$182,846
T32 · FY2012 · AI · contact PI
Characterization of cell GBV-C envelope glycoprotein interactions$0
I01 · FY2012 · VA · contact PI
GBV-C effects on CD4 activation and expansion$530,688
R01 · FY2011 · AI · contact PI
Research Training in Infectious Diseases$96,015
T32 · FY2011 · AI · contact PI
Characterization of cell GBV-C envelope glycoprotein interactions$0
I01 · FY2011 · VA · contact PI
Characterization of cell GBV-C envelope glycoprotein interactions$0
I01 · FY2011 · VA · contact PI
GBV-C effects on CD4 activation and expansion$525,482
R01 · FY2010 · AI · contact PI
GBV-C effects on CD4 activation and expansion$235,649
R01 · FY2010 · AI · contact PI
Research Training in Infectious Diseases$200,700
T32 · FY2010 · AI · contact PI
GBV-C effects on CD4 activation and expansion$531,982
R01 · FY2009 · AI · contact PI
Characterization of cell GBV-C envelope glycoprotein interactions$0
I01 · FY2009 · VA · contact PI
GB Virus type C Natural History, Epidemiology, HIV Interaction$617,141
R01 · FY2008 · AI · contact PI
Research Training in Infectious Diseases$250,689
T32 · FY2008 · AI · contact PI
GB Virus type C Natural History, Epidemiology, HIV Interaction$610,851
R01 · FY2007 · AI · contact PI
Research Training in Infectious Diseases$202,358
T32 · FY2007 · AI · contact PI
GBV-C Natural History, Epidemiology, HIV Interaction$610,854
R01 · FY2006 · AI · contact PI
Research Training in Infectious Diseases$248,796
T32 · FY2006 · AI · contact PI
SMALLPOX VACCINATION ON ENDOTHELIAL FUNCTION AND HUMAN GENE EXPRESSION$331
M01 · FY2006 · RR · contact PI
GBV-C Natural History, Epidemiology, HIV Interaction$607,417
R01 · FY2005 · AI
Research Training in Infectious Diseases$249,429
T32 · FY2005 · AI
SMALLPOX VACCINATION ON ENDOTHELIAL FUNCTION AND HUMAN GENE EXPRESSION$16,511
M01 · FY2005 · RR
EFFECTS OF STATINS ON HEPATITIS C AND GBV-C VIRAL LOADS$4,533
M01 · FY2005 · RR
EFFECT OF GB VIRUS C INFECTION ON HIV INFECTION, CD4 CELL COUNTS AND HIV RNA$1,578
M01 · FY2005 · RR
GBV-C Natural History, Epidemiology, HIV Interaction$663,858
R01 · FY2004 · AI
Research Training in Infectious Diseases$190,549
T32 · FY2004 · AI
ACTG A5088 Interleukin-2 and Pegylated Interferon$17,343
M01 · FY2004 · RR
Aventis Pasteur's Smallpox Vaccine in Vaccinia-Naive$15,179
M01 · FY2004 · RR
Effects of Statins on Hepatitis C and GBV-C Viral Loads$10,794
M01 · FY2004 · RR
Informed Consent to Use Stored Human Biological Materials$3,614
M01 · FY2004 · RR
SMALLPOX VACCINATION ON ENDOTHELIAL FUNCTION$675
M01 · FY2004 · RR
ACTG 368--159U89 WITH INDIVAVIR SULFATE AND DMP266 IN HIV SUBJECTS$0
M01 · FY2002 · RR
ACTG 343--THREE MAINTENANCE REGIMENS FOR HIV INFECTED SUBJECTS$0
M01 · FY2002 · RR
CLINICAL EVALUATION OF ECHINACEA AND HYPERICUM IN HIV-1 INFECTED SUBJECTS$0
P01 · FY2002 · ES
TREATMENT ROLLOVER FOR PTS FORMERLY ON ACTG 328: IL-2$0
M01 · FY2002 · RR
TRIAL OF IV WF10 (TCDO) IN PATIENTS WITH LATE STAGE HIV DISEASE$0
M01 · FY2002 · RR
ACTG 5025 HYDROXYUREA AND POTENT ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
ACTG 388 TRIAL OF EFZ OR NFV WITH LAMIVUDINE/ZDV &INDINAVIR IN HIV INFECTION$0
M01 · FY2002 · RR
ACTG 384, PROTEASE &NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR HIV$0
M01 · FY2002 · RR
ACTG 398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN HIV$0
M01 · FY2002 · RR
TRIPLE COMBINATION DRUG THERAPY FOR HIV 1 SUBJECTS$0
M01 · FY2002 · RR
ACTG 372--VIROLOGIC SUCCESS OF INDINAVIR WITH NUCLEOSIDE ANALOGS IN HIV$0
M01 · FY2002 · RR
ACTG 328--RECOMBINANT HUMAN INTERLEUKIN 2 IN SUBJECTS WITH HIV$0
M01 · FY2002 · RR
Evaluation of GB virus C replication and HIV inhibition$325,345
R21 · FY2001 · AI
HCV-ALCOHOL INTERACTIONS-- PATHOGENESIS AND EPIDEMIOLOGY$273,679
R01 · FY2001 · AA
ACTG 343--THREE MAINTENANCE REGIMENS FOR HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
TREATMENT ROLLOVER FOR PTS FORMERLY ON ACTG 328: IL-2$0
M01 · FY2001 · RR
TRIAL OF IV WF10 (TCDO) IN PATIENTS WITH LATE STAGE HIV DISEASE$0
M01 · FY2001 · RR
ACTG 5025 HYDROXYUREA AND POTENT ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
ACTG 388 TRIAL OF EFZ OR NFV WITH LAMIVUDINE/ZDV &INDINAVIR IN HIV INFECTION$0
M01 · FY2001 · RR
ACTG 384, PROTEASE &NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR HIV$0
M01 · FY2001 · RR
ACTG 398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN HIV$0
M01 · FY2001 · RR
TRIPLE COMBINATION DRUG THERAPY FOR HIV 1 SUBJECTS$0
M01 · FY2001 · RR
ACTG 372--VIROLOGIC SUCCESS OF INDINAVIR WITH NUCLEOSIDE ANALOGS IN HIV$0
M01 · FY2001 · RR
ACTG 328--RECOMBINANT HUMAN INTERLEUKIN 2 IN SUBJECTS WITH HIV$0
M01 · FY2001 · RR
ACTG 368--159U89 WITH INDIVAVIR SULFATE AND DMP266 IN HIV SUBJECTS$0
M01 · FY2001 · RR
HCV-ALCOHOL INTERACTIONS-- PATHOGENESIS AND EPIDEMIOLOGY$265,707
R01 · FY2000 · AA
DELAVIRDINE MESYLATE WITH ZIDOVUDINE VS ZDV ALONE IN HIV1 SUBJECTS$22,028
M01 · FY2000 · RR
ACTG 368--159U89 WITH INDIVAVIR SULFATE AND DMP266 IN HIV SUBJECTS$22,028
M01 · FY2000 · RR
ACTG 343--THREE MAINTENANCE REGIMENS FOR HIV INFECTED SUBJECTS$22,028
M01 · FY2000 · RR
EFFECTS OF ALCOHOL ON HIV REPLICATION$22,028
M01 · FY2000 · RR
NEVIRAPINE, LAMIVUDINE AND BACKGROUND NUCLEOSIDE THERAPY IN AIDS$22,028
M01 · FY2000 · RR
ACTG 384, PROTEASE &NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR HIV$22,028
M01 · FY2000 · RR
ACTG 398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN HIV$22,028
M01 · FY2000 · RR
TRIPLE COMBINATION DRUG THERAPY FOR HIV 1 SUBJECTS$22,028
M01 · FY2000 · RR
ACTG 372--VIROLOGIC SUCCESS OF INDINAVIR WITH NUCLEOSIDE ANALOGS IN HIV$22,028
M01 · FY2000 · RR
ACTG 328--RECOMBINANT HUMAN INTERLEUKIN 2 IN SUBJECTS WITH HIV$22,028
M01 · FY2000 · RR
TREATMENT ROLLOVER FOR PTS FORMERLY ON ACTG 328: IL-2$0
M01 · FY2000 · RR
TRIAL OF IV WF10 (TCDO) IN PATIENTS WITH LATE STAGE HIV DISEASE$0
M01 · FY2000 · RR
ACTG 5025 HYDROXYUREA AND POTENT ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
ACTG 388 TRIAL OF EFZ OR NFV WITH LAMIVUDINE/ZDV &INDINAVIR IN HIV INFECTION$0
M01 · FY2000 · RR